Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.

Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.

The RTS,S/AS02(D) vaccine has been shown to have a promising safety profile, to be immunogenic and to confer protection against malaria in children and infants.We did a randomized, controlled, phase I/IIb trial of RTS,S/AS02(D) given at 10, 14 and 18 weeks of age staggered with routine immunization...

Full description

Bibliographic Details
Main Authors: Pedro Aide, John J Aponte, Montse Renom, Tacilta Nhampossa, Jahit Sacarlal, Inacio Mandomando, Quique Bassat, Maria Nélia Manaca, Amanda Leach, Marc Lievens, Johan Vekemans, Marie-Claude Dubois, Christian Loucq, W Ripley Ballou, Joe Cohen, Pedro L Alonso
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-11-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2973956?pdf=render

Internet

http://europepmc.org/articles/PMC2973956?pdf=render

Similar Items